TCR2 Therapeutics Appoints Leading Biotech Analyst Ian Somaiya as Chief Financial Officer

CAMBRIDGE, Mass., April 10, 2018 -- (Healthcare Sales & Marketing Network) -- TCR2 Therapeutics Inc., an immuno-oncology company pioneering a novel class of T cell receptor (TCR)-based cellular therapies for solid tumors and blood cancers, announced today... Biopharmaceuticals, Oncology, Personnel TCR2 Therapeutics, TRuC , immunotherapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news